This clinical trial is focused on studying a type of prostate cancer known as metastatic castration-resistant prostate cancer (mCRPC). This is a form of prostate cancer that continues to grow and spread even when the amount of male hormones in the body is reduced to very low levels. The study is comparing two treatments: Ifinatamab Deruxtecan, also known by its code name I-DXd, and Docetaxel. Ifinatamab Deruxtecan is a new treatment being tested, while Docetaxel is a chemotherapy drug that is already used to treat this type of cancer.
The purpose of the study is to see which treatment is more effective in helping patients live longer and in slowing down the progression of the cancer as seen on scans. Participants in the study will receive either Ifinatamab Deruxtecan or Docetaxel. The study will monitor how long patients live and how long it takes for the cancer to get worse. The study will also look at other factors, such as how long it takes before patients need another treatment, how the cancer responds to the treatment, and any side effects experienced by the participants.
Participants will be closely monitored throughout the study, which will include regular check-ups and scans to assess the progress of the cancer. The study aims to provide valuable information on the effectiveness and safety of Ifinatamab Deruxtecan compared to Docetaxel in treating metastatic castration-resistant prostate cancer.
1initial assessment
Upon joining the study, an initial assessment will be conducted to confirm eligibility. This includes reviewing medical history and current health status.
A series of tests may be performed to ensure the presence of metastatic castration-resistant prostate cancer, as well as to document any previous treatments and their outcomes.
2treatment assignment
Participants will be randomly assigned to receive either ifinatamab deruxtecan or docetaxel. This assignment is done to compare the effectiveness of the two treatments.
The assignment is open-label, meaning both the participant and the medical team will know which treatment is being administered.
3treatment administration
If assigned to ifinatamab deruxtecan, the medication will be administered through an intravenous infusion. The frequency and dosage will be determined by the medical team based on individual health needs.
If assigned to docetaxel, this medication will also be administered via intravenous infusion. The medical team will provide specific instructions regarding dosage and frequency.
4regular monitoring
Throughout the study, regular monitoring will be conducted to assess health status and treatment effectiveness. This includes physical examinations, blood tests, and imaging studies such as CT or MRI scans.
Participants will be monitored for any side effects or adverse reactions to the treatment. Adjustments to the treatment plan may be made based on these observations.
5follow-up assessments
Follow-up assessments will be scheduled to evaluate overall survival and progression-free survival. These assessments help determine the impact of the treatment on the cancer’s progression.
Additional evaluations may include measuring the time to first subsequent therapy, response rates, and any changes in symptoms or quality of life.
6completion of study
Upon completion of the study, a final assessment will be conducted to gather comprehensive data on the treatment’s effectiveness and any long-term effects.
Participants will receive information on any further steps or treatments that may be recommended based on the study’s findings.
Who Can Join the Study?
Must have a confirmed diagnosis of adenocarcinoma of the prostate, which is a type of prostate cancer, and it should not have small cell features.
Must have experienced prostate cancer progression while on androgen deprivation therapy (ADT), which is a treatment to lower male hormones, or after surgical removal of the testicles, within 6 months before the screening for the study.
Must have current evidence of cancer that has spread to other parts of the body, shown by bone lesions on a bone scan or soft tissue disease visible on a CT or MRI scan.
Must have received prior treatment with 1 or 2 androgen receptor pathway inhibitors (ARPIs), which are drugs that block male hormones, and the cancer must have progressed during or after at least 8 weeks of treatment.
Must have provided a sample of tumor tissue from a biopsy, which is a procedure to remove a small piece of tissue for testing, from an area not previously treated with radiation, and this sample should be obtained after the disease worsened on the most recent therapy.
Must have recovered from any side effects caused by previous cancer treatments.
Who Cannot Join the Study?
Patients with Metastatic Castration-Resistant Prostate Cancer cannot participate if they have other serious health conditions that might interfere with the study.
Patients who have had another type of cancer in the past, unless it was treated and has not come back for at least 5 years, are not eligible.
Patients who are currently receiving treatment with other experimental drugs or have done so within a certain period before the study starts cannot join.
Patients with known allergies to the study drugs or similar drugs are excluded.
Patients with certain heart conditions or who have had a heart attack in the past 6 months are not eligible.
Patients with uncontrolled high blood pressure cannot participate.
Patients with active infections, including HIV, hepatitis B, or hepatitis C, are excluded.
Patients who have had major surgery within a certain period before the study starts are not eligible.
Patients with a history of brain or spinal cord conditions that could affect the study are excluded.
Patients who are unable to follow the study procedures or comply with the study requirements cannot participate.
Ifinatamab Deruxtecan is a medication being studied for its potential to treat metastatic castration-resistant prostate cancer, a type of prostate cancer that continues to grow even when the amount of testosterone in the body is reduced to very low levels. This medication is designed to target and deliver a powerful anti-cancer agent directly to the cancer cells, which may help to slow down or stop the growth of the cancer. The goal of using Ifinatamab Deruxtecan in this study is to see if it can help patients live longer and delay the progression of their cancer compared to another treatment option.
Docetaxel is a well-known chemotherapy drug used to treat various types of cancer, including prostate cancer. It works by interfering with the growth and division of cancer cells, which can help to slow down or stop the spread of the disease. In this study, Docetaxel is being used as a comparison to see how well Ifinatamab Deruxtecan performs in helping patients with metastatic castration-resistant prostate cancer. The study aims to determine which treatment is more effective in improving the survival and quality of life for these patients.
Metastatic Castration-Resistant Prostate Cancer – This is a type of prostate cancer that continues to grow and spread to other parts of the body despite treatments that lower testosterone levels. It typically progresses by spreading to bones, lymph nodes, and other organs. The cancer cells in this condition are resistant to hormonal therapy, which is usually effective in controlling prostate cancer. As the disease advances, patients may experience symptoms such as bone pain, urinary issues, and fatigue. The progression is often monitored through imaging studies and blood tests measuring prostate-specific antigen (PSA) levels. Over time, the cancer may lead to complications such as fractures or spinal cord compression due to bone metastases.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Austria 
Czechia 
Denmark 
France 
Germany 
Greece 
Ireland 
Italy 
Norway 
Poland 
Spain 
Sweden 
The Netherlands 